Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 8, 2009, Pages 2179-2185

  Zhang, Penglie ^a   Huang, Wenrong ^a   Wang, Lingyan ^a   Bao, Liang ^a   Jia, Zhaozhong J ^a   Bauer, Shawn M ^a   Goldman, Erick A ^a   Probst, Gary D ^a   Song, Yonghong ^a   Su, Ting ^a   Fan, Jingmei ^a   Wu, Yanhong ^a   Li, Wenhao ^a   Woolfrey, John ^a   Sinha, Uma ^a   Wong, Paul W ^a   Edwards, Susan T ^a   Arfsten, Ann E ^a   Clizbe, Lane A ^a   Kanter, James ^a   Pandey, Anjali ^a   Park, Gary ^a   Hutchaleelaha, Athiwat ^a   Lambing, Joseph L ^a   Hollenbach, Stanley J ^a   Scarborough, Robert M ^a   Zhu, Bing Yan ^a   more..

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PHENYL GROUP; POTASSIUM CHANNEL HERG; PRT 054021; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BENZAMIDES; CATALYTIC DOMAIN; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; FACTOR XA; HUMANS; MACACA FASCICULARIS; PYRIDINES; RABBITS; RATS;

EID: 63149141508     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.111     Document Type: Article

References (51)

1. Mann K.G., Jenny R.J., and Krishnaswamy S. Annu. Rev. Biochem. 57 (1988) 915
2. Mann K.G., Butenas S., and Brummel K. Arterioscler. Thromb. Vas. Biol. 23 (2003) 17
3. Schaffer L.W., Davidson J.T., Vlasuk G.P., Dunwiddie C.T., and Siegl P.K.S. Arterioscler. Thromb. 12 (1992) 879
4. Zhu B.-Y., and Scarborough R.M. Annu. Rep. Med. Chem. 35 (2000) 83
5. Linkins L.-A., Julian J.A., Rischke J., Hirsh J., and Weitz J.I. Thromb. Res. 105 (2002) 241
6. Walenga J.M., Jeske W.P., Hoppensteadt D., and Fareed J. Curr. Opin. Invest. Drugs 4 (2003) 272
7. Samama M.M. Thromb. Res. 106 (2002) V267
8. Kaiser B. Cell. Mol. Life Sci. 59 (2002) 189
9. McBride B.F. J. Clin. Pharm. 45 (2005) 1004
10. Saiah E., and Soares C.S. Curr. Top. Med. Chem. 5 (2005) 1677
11. Roehrig S., Straub A., Pohlmann J., Lampe T., Pererstorfer J., Schlemmer K.-H., Reinemer P., and Perzborn E. J. Med. Chem 48 (2005) 5900
12. Perzborn E., Strassburger J., Wilmen A., Pohlmann J., Roehrig S., Schlemmer K.-H., and Straub A. J. Thromb. Haemostasis 3 (2005) 514
13. Eriksson B.L., Borris L., Dahl O.E., Haas S., Huisman M.V., and Kakkar A.K. J. Thromb. Haemostasis 4 (2006) 121
14. Quan M.L., Lam P.Y.S., Han Q., Pinto D.J.P., He M.Y., Li R., Ellis C.D., Clark C.G., Teleha C.A., Sun J.-H., Alexander R.S., Bai S., Luettegn J.M., Knabb R.M., Wong P.C., and Wexler R.R. J. Med. Chem 48 (2005) 1729
15. Wong P.C., Crain E.J., Watson C.A., Wexler R.R., Lam P.Y.S., Quan M.L., and Knabb R.M. J. Thromb. Thrombolysis 24 (2007) 43
16. Pinto D.J.P., Orwat M.J., Koch S., Rossi K.A., Alexander R.S., Smallwood A., Wong P.C., Rendina A.R., Luettgen J.M., Knabb R.M., He K., Xin B., Wexler R.R., and Lam P.Y.S. J. Med. Chem 50 (2007) 5339
17. Furugohri T., Isobe K., Honda Y., Kamisato-Matsumoto C., Sugiyama N., Nagahara T., Morishima Y., and Shibano T. J. Thromb. Haemostasis 6 (2008) 1542
18. Turpie A.G., Bauer K.A., Erilsson B.I., and Lassen M.R. Arch. Intern. Med 162 (2002) 1833
19. Zhang, P.; Bao, L.; Zuckett, J. F.; Jia, Z. J.; Sinha, U.; Park, G.; Hutchaleelaha, A.; Scarborough, R. M.; Zhu, B.-Y. Bioorg. Med. Chem. Lett. 2009, 19, 2186, the preceding communication, doi:10.1016/j.bmcl.2009.02.114.
20. 50 values were determined by the method described in:. Sinha U., Ku P., Malinowski J., Zhu B.Y., Scarborough R.M., Marlowe C.K., Wong P.W., Lin P.H., and Hollenbach S.J. Eur. J. Pharmacol. 395 (2000) 51
21. i values were determined by the method described in:. Betz A., Wong P.W., and Sinha U. Biochemistry 38 (1999) 14582
22. For description of our human plasma-based thrombin generation assay (2×TG), see:. Sinha U., Lin P.H., Edwards S.T., Wong P.W., Zhu B., Scarborough R.M., Su T., Jia Z.J., Song Y., Zhang P., Clizbe L., Park G., Reed A., Hollenbach S.J., Malinowski J., and Arfsten A.E. Arterioscler. Thromb. Vas. Biol. 23 (2003) 1098
23. Several other laboratories have also investigated anthranilamide-derived fXa inhibitors:. Yee Y.K., Tebbe A.L., Linebarger J.H., Beight D.W., Craft T.J., Gifford-Moore D., Goodson Jr. T., Herron D.K., Klimkowski V.J., Kyle J.A., Sawyer J.S., Smith G.F., Tinsley J.M., Towner R.D., Weir L., and Wiley M.R. J. Med. Chem. 43 (2000) 873
24. Shrader W.D., Young W.B., Sprengler P.A., Sangalang J.C., Elrod K., and Carr G. Bioorg. Med. Chem. Lett. 11 (2001) 1801
25. Chou Y.-L., Davey D.D., Eagen K.A., Griedel B.D., Karanjawala R., Philips G.B., Sacchi K.L., Shaw K.J., Wu S.C., Lentz D., Liang A.M., Trin L., Morrissey M.M., and Kochanny M.J. Bioorg. Med. Chem. Lett. 13 (2003) 507
26. Kochanny M.J., Alder M., Ewing J., Griedel B.D., Ho E., Karanjawala R., Lee W., Lentz D., Liang A.M., Morrissey M.M., Phillips G.B., Post J., Sacchi K.L., Sakata S.T., Subramanyam B., Vergona R., Walters J., White K.A., Whitlow M., Ye B., Zhao Z., and Shaw K.J. Bioorg. Med. Chem. 15 (2007) 2127
27. Ye B., Arniaz D.O., Chuo Y.-L., Griedel B.D., Karanjawala R., Lee W., Morrissey M.M., Sacchi K.L., Sakata S.T., Shaw K.J., Wu S.C., Zhao Z., Adler M., Cheeseman S., Dole W.P., Ewing J., Fitch R., Lentz D., Liang A., Light D., Morser J., Post J., Rumennik G., Subramanyam B., Sullivan M.E., Vergona R., Walters J., Wang Y.-X., White K.A., Whitlow M., and Kochanny M.J. J. Med. Chem. 50 (2007) 2967
28. Mendel D., Marquart A.L., Joseph S., Waid P., Yee Y.K., Tebbe A.L., Ratz A.M., Herron D.K., Goodson T., Masters J.J., Franciskovich J.B., Tinsley J.M., Wiley M.R., Weir L.C., Kyle J.A., Klimkowski V.J., Smith G.F., Towner R.D., Froelich L.L., Buben J., and Craft T.J. Bioorg. Med. Chem. Lett. 17 (2007) 4832
29. Corte J.R., Fang T., Pinto D.J.P., Han W., Hu Z., Jiang X.-J., Li Y.-L., Gauuan J.F., Hadden M., Orton D., Rendina A.R., Luettgen J.M., Wong P.C., He K., Morin P.E., Chang C.-W., Cheney D.L., Knabb R.M., Wexler R.R., and Lam P.Y.S. Bioorg. Med. Chem. Lett. 18 (2008) 2845
30. Jones G., Willet P., Glen R.C., Leach A.R., and Taylor R. J. Mol. Biol. 267 (1997) 727
31. Adler M., Kochanny M.J., Ye B., Rumennik G., Light D.R., Biancalana S., and Whitlow M. Biochemistry 41 (2002) 15514
32. In vitro liver metabolic stability was determined using liver S9 fractions and expressed as half-life: Compounds (1 μM) were incubated with liver S9 proteins (1 mg/mL) and a NADPH regenerating system (NADP + glucose-6-phosphate) suspended in phosphate buffer (100 mM). Samples were taken at t = 0, 5, 10, 15 and 60 min. and added to an organic solvent to terminate the reaction. After adding an internal standard, the mixtures were centrifuged and the supernatant transferred to HPLC vials. Samples were analyzed by tandem-mass spectrometry. The change in area ratio (substrate/internal standard) between t = 0 and 15 min was used to estimate half-life. Coumarin 7-hydroxylase (CYP2A6), caffeine demethylase (CYP1A2), verapamil (CYP3A4) and/or propanolol (CYP3A4) were used as positive control. For negative controls, substrates were incubated with heat inactivated (60 min at 60 °C) liver S9 fractions.
33. Jia Z.J., Wu Y., Huang W., Zhang P., Song Y., Woolfrey J., Sinha U., Arfsten A.E., Edwards S.T., Hutchaleelaha A., Hollenbach S.J., Lambing J.L., Scarborough R.M., and Zhu B.-Y. Bioorg. Med. Chem. Lett. 14 (2004) 1229
34. Jia Z.J., Su T., Zuckett J.F., Wu Y., Goldman E.A., Li W., Zhang P., Clizbe L.A., Song Y., Bauer S.M., Huang W., Woolfrey J., Sinha U., Arfsten A.E., Hutchaleelaha A., Hollenbach S.J., Lambing J.L., Scarborough R.M., and Zhu B.-Y. Bioorg. Med. Chem. Lett. 14 (2004) 2073
35. Zhu B.-Y., Jia Z.J., Zhang P., Su T., Huang W., Goldman E., Tumas D., Kadambi V., Eddy P., Sinha U., Scarborough R.M., and Song Y. Bioorg. Med. Chem. Lett. 16 (2006) 5507
36. Finalayson K., Turnbull L., January C.T., Sharkey J., and Kelly J.S. Eur. J. Pharmacol. 430 (2001) 147
37. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., and Montanaro N. Drug Saf. 25 (2002) 263
38. Mitcheson J.S., and Perry M.D. Curr. Opin. Drug Disc. Dev. 6 (2003) 667
39. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., Mackenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., Wallis R., Camm A.J., and Hammond T.G. Cardiovas. Res. 58 (2003) 32
40. Shah R.R. Drug Saf. 28 (2005) 115
41. Waring M.J., and Johnstone C. Bioorg. Med. Chem. Lett. 17 (2007) 1759
42. Jamieson C., Moir E.M., Rankovic Z., and Wishart G. J. Med. Chem. 49 (2006) 5029
43. Sinha U., Edwards S.T., Wong P.W., Delaney S.M., Nanda N., Marzec U.M., Pak Y., Hollenbach S.J., Hanson S.R., and Scarborough R.M. Blood 108 (2006) Abstract 907
44. Abe K., Siu G., Edwards S., Lin P.H., Zhu B.-Y., Marzec U.M., Hanson S.R., Pak Y., Hollenbach S.J., and Sinha U. Blood 108 (2006) Abstract 901
45. The rabbit 2×PT values were determined by the method described in Ref. 5(b).
46. Human plasma protein binding, expressed as unbound fraction, was determined by this protocol: The compound stock solutions were diluted in 1.0 M HEPES (pH 7.4) to yield a 1.0 mM working solution. The working solution was added to plasma samples (EDTA was used as anticoagulant) in a ratio of 1/100 yielding a final concentration of 10 μM. The mixture was gently mixed and incubated at 37 °C for 30 min. At the conclusion of the incubation 3 aliquots (450 μL) each were added to a centrifugal filter device fitted to a 96 well plate. Standards were prepared in protein free human plasma and transferred to the centrifugal filter device fitted to the same plate. The plates were centrifuged for 25 min at 32 °C in a centrifuge. 15 μL each of the filtrate was transferred to a round bottom 96 well plate and 15 μL of acetonitrile including KN1022 (1 μg/mL) as internal standard was added followed by 60 μL of DI water. Plates were placed on a Multi-Tube Vortexer for 30 s and vortexed. Concentrations in the filtrate were determined by LC/MS/MS and using standard curves prepared in ultra filtrated plasma.
47. Kr current generated under normoxic conditions. Interference of the potassium channel suggests that the compound could modify (shorten or prolong) the electrocardiographic (ECG) QT interval. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., and January C.T. Biophys. J. 74 (1998) 230
48. Zhou Z., Gong Q., Ye B., Fan F., Makielski J.C., Robertson G.A., and January C.T. Biophys. J. 72 (1997) A225
49. Hancox J.C., Levi A.J., and Witchel H.J. Pflugers Arch. 436 (1998) 843
50. Jurkat-Rott K., and Lehmann-Horn F. Curr. Pharm. Biotechnol. 5 (2004) 387
51. Turpie A.G.G., Bauer K.A., Davidson B.L., Fisher W.D., Gent M., Huo M.H., Sinha U., and Gretlet D.D. Thromb. Haemostasis 101 (2009) 68